Opthea Ltd (CKDXF PINK) stock market data APIs
$0.0101
0.28(2772.3%)
as of September 7, 2026
Try our APIs with
free plan!
Opthea Ltd Financial Data Overview
Price chart is built with
Anychart
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.
Prev. Close
0.0101
Open
0.287
High
0.2901
Low
0.0101
52 wk Range
0.01-0.44
Market Cap
13 680 K
P/E Ratio
0.0556
Shares Outstanding
1 368 M
Revenue
1 000
Beta
1.489
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Opthea Ltd data using free add-ons & libraries
Get Opthea Ltd Fundamental Data
Opthea Ltd Fundamental data includes:
- Net Revenue: 1 000
- EBITDA: -11 937 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Opthea Ltd News
New
Opthea Receives A$8.7 million R&D Tax Incentive
Opthea Limited MELBOURNE, Australia, March 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly pre...
Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference
Opthea Limited MELBOURNE, Australia, March 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly pre...
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
Opthea Limited MELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prev...
Opthea To Present at SVB Leerink Global Biopharma Conference
Opthea Limited MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prev...
Get Opthea Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
